文献速递肾移植

HLA相合肾移植受者诱导治疗的使用与结局

Use and Outcomes of Induction Therapy in Well-Matched Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-01-01

该观察性研究基于美国器官获取与移植网络数据,纳入2976例HLA-A、-B、-DR、-DQB1血清学配型相合的首例成人肾移植受者,57%接受T细胞清除抗体、28%接受IL-2受体拮抗剂、15%未接受诱导治疗;IL-2受体拮抗剂与无诱导治疗组移植物存活无差异,T细胞清除治疗组移植物丢失风险与IL-2受体拮抗剂或无诱导治疗相似(HR 1.19,95%CI 0.98-1.45),1年急性排斥发生率低(≤5%)且组间无差异。

要点

  • HLA-A、-B、-DR、-DQB1配型相合肾移植受者中,57%使用T细胞清除抗体、28%使用IL-2受体拮抗剂、15%未诱导。
  • IL-2受体拮抗剂与无诱导治疗组间同种异体移植物存活、死亡删失移植物存活或带功能死亡无差异。
  • T细胞清除治疗组移植物丢失(含死亡)风险与IL-2受体拮抗剂或无诱导治疗相似(HR 1.19,95%CI 0.98-1.45)。

核心结论

  • 在HLA-A、-B、-DR、-DQB1位点与供者配型相合的首例肾移植受者中,使用T细胞清除治疗或IL-2受体拮抗剂诱导治疗与移植后结局改善无关。

研究设计与样本

  • 观察性研究,数据来自美国器官获取与移植网络,纳入首例成人肾移植受者,共2976例。

主要发现

  • 2976例受者中57%接受T细胞清除抗体、28%接受IL-2受体拮抗剂、15%未接受诱导治疗。
  • IL-2受体拮抗剂组与无诱导治疗组间同种异体移植物存活、死亡删失移植物存活或带功能死亡无差异。
  • 多变量模型中,T细胞清除治疗组与IL-2受体拮抗剂或无诱导治疗相比,移植物丢失(含死亡)风险相似(HR 1.19,95%CI 0.98-1.45)。
  • 在黑种受者、按计算群体反应性抗体分组及供者来源亚组分析中结果一致。
  • 1年急性排斥发生率低(≤5%),且各治疗组间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The optimal induction treatment in low-immune risk kidney transplant recipients is uncertain. We therefore investigated the use and outcomes of induction immunosuppression in a low-risk cohort of patients who were well matched with their donor at HLA-A, -B, -DR, -DQB1 on the basis of serologic typing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our study was an observational study of first adult kidney-only transplant recipients in the United States recorded by the Organ Procurement and Transplant Network. RESULTS: Among 2976 recipients, 57% were treated with T cell-depleting antibodies, 28% were treated with an IL-2 receptor antagonist, and 15% were treated without induction. There was no difference in allograft survival, death-censored graft survival, or death with function between patients treated with an IL-2 receptor antagonist and no induction therapy. In multivariable models, patients treated with T cell-depleting therapy had a similar risk of graft loss from any cause, including death (hazard ratio, 1.19; 95% confidence interval, 0.98 to 1.45), compared with patients treated with an IL-2 receptor antagonist or no induction. The findings were consistent in subgroup analyses of Black recipients, patients grouped by calculated panel reactive antibody, and donor source. The incidence of acute rejection at 1 year was low (≤5%) and did not vary between treatment groups. CONCLUSIONS: Use of induction therapy with T cell-depleting therapy or IL-2 receptor antagonists in first kidney transplant recipients who are well matched with their donor at the HLA-A, -B, -DR, -DQB1 gene loci is not associated with improved post-transplant outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Evans RDR, Lan JH, Kadatz M, et al. Use and Outcomes of Induction Therapy in Well-Matched Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2022. PMID: 35131930. doi:10.2215/CJN.09170721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。